FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070479156> ?p ?o ?g. }

• W2070479156 endingPage "47" @default.
• W2070479156 startingPage "39" @default.
• W2070479156 abstract "A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn's disease. Crohn's disease is initiated by an innate immune response, which eventuates in a T-cell driven process, characterized by a T-helper cell 1 type cytokine profile. Several new treatments now focus on suppressing T-cell differentiation or T-cell inflammation. Since inflammatory bowel disease (IBD) represents a state of dysregulated inflammation, drugs that augment the anti-inflammatory response have the potential to downregulate inflammation and thereby hopefully modify the disease. Tumour necrosis factor (TNF) is a major target of research and clinical investigation. TNF has proinflammatory effects in the intestinal mucosa and is a pivotal cytokine in the inflammatory cascade. Certolizumab pegol (CDP870) is a PEGylated, Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody. PEGylation increases the half-life, reduces the requirement for frequent dosing, and possibly reduces antigenicity as well. Certolizumab has been shown in Phase III trials to achieve and maintain clinical response and remission in Crohn's disease patients. It improves the quality of life. Certolizumab pegol will be indicated for moderately to severely active Crohn's disease, but it is not yet licensed in Europe or the US. It is not possible to construct an algorithm for treatment, but when compared with infliximab the two principal advantages are likely to be lower immunogenicity (as shown by anti-drug antibodies, absence of infusion reactions, and low rate of antinuclear antibodies), and a subcutaneous route of administration. These two factors may be sufficient to promote it up the pecking order of anti-TNF agents." @default.
• W2070479156 created "2016-06-24" @default.
• W2070479156 creator A5056474210 @default.
• W2070479156 creator A5090010726 @default.
• W2070479156 date "2007-03-01" @default.
• W2070479156 modified "2023-10-12" @default.
• W2070479156 title "Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870)" @default.
• W2070479156 cites W124041597 @default.
• W2070479156 cites W1522944862 @default.
• W2070479156 cites W1607808246 @default.
• W2070479156 cites W1666594451 @default.
• W2070479156 cites W1671682816 @default.
• W2070479156 cites W1774343840 @default.
• W2070479156 cites W1964785646 @default.
• W2070479156 cites W1965067289 @default.
• W2070479156 cites W1976546496 @default.
• W2070479156 cites W1995661596 @default.
• W2070479156 cites W1997329576 @default.
• W2070479156 cites W1997999969 @default.
• W2070479156 cites W1998740583 @default.
• W2070479156 cites W2006712764 @default.
• W2070479156 cites W2044788893 @default.
• W2070479156 cites W2058003112 @default.
• W2070479156 cites W2058250733 @default.
• W2070479156 cites W2061918270 @default.
• W2070479156 cites W2070414885 @default.
• W2070479156 cites W2076952006 @default.
• W2070479156 cites W2094464340 @default.
• W2070479156 cites W2104784902 @default.
• W2070479156 cites W2106964599 @default.
• W2070479156 cites W2111570058 @default.
• W2070479156 cites W2114990062 @default.
• W2070479156 cites W2120419234 @default.
• W2070479156 cites W2130153850 @default.
• W2070479156 cites W2131882149 @default.
• W2070479156 cites W2135423184 @default.
• W2070479156 cites W2136488215 @default.
• W2070479156 cites W2140741976 @default.
• W2070479156 cites W2145135012 @default.
• W2070479156 cites W2148298419 @default.
• W2070479156 cites W2152026434 @default.
• W2070479156 cites W2162868329 @default.
• W2070479156 cites W2170301801 @default.
• W2070479156 cites W2171341132 @default.
• W2070479156 cites W2188248802 @default.
• W2070479156 cites W2294895147 @default.
• W2070479156 cites W2342579157 @default.
• W2070479156 cites W2420147178 @default.
• W2070479156 cites W4212952358 @default.
• W2070479156 cites W4231456852 @default.
• W2070479156 cites W4241611245 @default.
• W2070479156 cites W4255149626 @default.
• W2070479156 cites W4256456688 @default.
• W2070479156 cites W4375834904 @default.
• W2070479156 doi "https://doi.org/10.2147/nano.2007.2.1.39" @default.
• W2070479156 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2673818" @default.
• W2070479156 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17722511" @default.
• W2070479156 hasPublicationYear "2007" @default.
• W2070479156 type Work @default.
• W2070479156 sameAs 2070479156 @default.
• W2070479156 citedByCount "18" @default.
• W2070479156 countsByYear W20704791562013 @default.
• W2070479156 countsByYear W20704791562015 @default.
• W2070479156 countsByYear W20704791562016 @default.
• W2070479156 countsByYear W20704791562017 @default.
• W2070479156 countsByYear W20704791562020 @default.
• W2070479156 countsByYear W20704791562022 @default.
• W2070479156 crossrefType "journal-article" @default.
• W2070479156 hasAuthorship W2070479156A5056474210 @default.
• W2070479156 hasAuthorship W2070479156A5090010726 @default.
• W2070479156 hasBestOaLocation W20704791561 @default.
• W2070479156 hasConcept C126322002 @default.
• W2070479156 hasConcept C159654299 @default.
• W2070479156 hasConcept C17991360 @default.
• W2070479156 hasConcept C203014093 @default.
• W2070479156 hasConcept C2776215756 @default.
• W2070479156 hasConcept C2777138892 @default.
• W2070479156 hasConcept C2778260677 @default.
• W2070479156 hasConcept C2778690821 @default.
• W2070479156 hasConcept C2779134260 @default.
• W2070479156 hasConcept C2779280984 @default.
• W2070479156 hasConcept C2780132546 @default.
• W2070479156 hasConcept C542903549 @default.
• W2070479156 hasConcept C71924100 @default.
• W2070479156 hasConceptScore W2070479156C126322002 @default.
• W2070479156 hasConceptScore W2070479156C159654299 @default.
• W2070479156 hasConceptScore W2070479156C17991360 @default.
• W2070479156 hasConceptScore W2070479156C203014093 @default.
• W2070479156 hasConceptScore W2070479156C2776215756 @default.
• W2070479156 hasConceptScore W2070479156C2777138892 @default.
• W2070479156 hasConceptScore W2070479156C2778260677 @default.
• W2070479156 hasConceptScore W2070479156C2778690821 @default.
• W2070479156 hasConceptScore W2070479156C2779134260 @default.
• W2070479156 hasConceptScore W2070479156C2779280984 @default.
• W2070479156 hasConceptScore W2070479156C2780132546 @default.
• W2070479156 hasConceptScore W2070479156C542903549 @default.
• W2070479156 hasConceptScore W2070479156C71924100 @default.
• W2070479156 hasIssue "1" @default.

• next